

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



59

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C12N 15/00	A2	(11) International Publication Number: WO 98/39426 (43) International Publication Date: 11 September 1998 (11.09.98)
(21) International Application Number: PCT/US98/04291 (22) International Filing Date: 5 March 1998 (05.03.98) (30) Priority Data: 08/812,121 5 March 1997 (05.03.97) US (71) Applicant (for all designated States except US): UNIVERSITY OF NEBRASKA BOARD OF REGENTS [US/US]; Regents Hall, 3835 Holdrege Street, Lincoln, NE 68598 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TRACY, Steven, M. [US/US]; 1622 N. 53rd Street, Omaha, NE 68104 (US). CHAPMAN, Nora, M. [US/US]; 1622 N. 53rd Street, Omaha, NE 68104 (US). KOLBECK, Peter [US/US]; 1416 Kingsford Drive, Carmichael, CA 95608 (US). MALONE, James [US/US]; 3420 South 50th Street, Omaha, NE 68106 (US). (74) Agents: REED, Janet, E. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103-2307 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COXSACKIE VIRUS VECTORS FOR DELIVERY OF NUCLEIC ACIDS ENCODING ANTIGENIC OR THERAPEUTIC PRODUCTS (57) Abstract <p>The present invention is drawn to the use of attenuated Coxsackie virus cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory or other biologically active proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Additionally, other organs or tissues may be targeted with specific picornaviruses. In particular, an attenuated CVB3 viral vector able to express a cytokine is provided. This cytokine-expressing viral vector is able to deliver the cytokine to a target tissue and reduce disease symptoms.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Moogolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**COXSACKIE VIRUS VECTORS FOR DELIVERY OF NUCLEIC ACIDS
ENCODING ANTIGENIC OR THERAPEUTIC PRODUCTS**

This invention was produced in part using funds obtained through a grant from the National Institutes of Health. Consequently, the United States government has certain rights in this invention.

5

FIELD OF THE INVENTION

The present invention relates generally to the fields of molecular biology and virology. More specifically, the present invention relates to a
10 biologically engineered, attenuated Cocksackievirus and its use as a delivery vehicle for nucleic acids encoding antigenic or biologically active proteins.

BACKGROUND OF THE INVENTION

15

The coxsackieviruses, members of the family *Picornaviridae*, are divided into two groups, based essentially on their pathogenicity and replication in newborn mice. The Group B coxsackieviruses (CVB) are composed of six serotypes (1-6). Similar to other
20 members of the *Picornaviridae*, the CVB genome is a single-stranded, messenger sense, polyadenylated RNA molecule (for review see Romero, J.R. et al., *Current Topics in Microbiology and Immunology* 223: 97-152, 1997). Genome analysis of the CVB shows that they are organized
25 into a 5' nontranslating region, a protein coding region containing a single open reading frame, a 3' nontranslated region and a terminal poly-A tail, similar to other *Picornaviruses*. The CVB protein coding region can be further divided into three regions, P1, P2 and P3.
30 P1 encodes the four capsid proteins VP4 (1A), VP2 (1B), VP3 (1C) and VP 1 (1D); P2 and P3 encode the non-structural proteins required for the CVB lifecycle: 2A

-2-

(protease), 2B, 2C, 3A 3B (Vpg), 3C (protease) and 3D (polymerase) (See Romero et al., 1997, supra).

The genomes of CVB that have been fully sequenced are very similar to one another in length, ranging from 7389 nucleotides (CVB1) to 7402 nucleotides (CVB5) (Romero et al., 1997 supra). Variations in length are due to differences within the coding region of VP1 and VP2 (capsid proteins) and in the 5' and 3' non-translated regions. The 5' non-translated regions also show remarkable similarity in length. For a detailed review of the similarities among the CVB genomes, refer to Romero et al, supra, 1997.

One of the six serotypes of the group B coxsackieviruses, Coxsackievirus B3 (CVB3), has been particularly well studied, and serves as a prototype for the other coxsackieviruses. The CVB3 genome is single molecule of positive sense RNA which encodes a 2,185 amino acid polyprotein. The single long open reading frame is flanked by a 5' non-translated region (5' NTR), 742 nucleotides long, and a much shorter 3' NTR which terminates in a polyadenylate tract. Like the polioviruses (PVs), CVB3 shuts off host cell protein translation in infected HeLa cells. The near atomic structure of the CVB3 virion has been solved, demonstrating that the CVB3 capsid shares a similar capsid structure with genetically-related entero-and rhinoviruses.

Coxsackie B viruses are established etiologic agents of acute human inflammatory heart disease (reviewed in Cherry, J.D. Infectious Diseases of the Fetus and Newborn Infant, 4th ed., pp.404-446, 1995) and cardiac CVB3 infections may lead to dilated cardiomyopathy. Systemic CVB3 infections are common in neonates: often severe or life-threatening, they usually involve inflammation and necrosis of the heart muscle. One study of neonates under three months of age suggested a CVB infection rate as high as 360/100,000 infants with

-3-

an associated 8% mortality (Kaplan, M.H., et al., *Rev. Infect. Dis.* 5:1019-1032, 1983). Acute and chronic inflammatory heart disease afflicts approximately 5 - 8 individuals per one hundred thousand population annually worldwide (Manolio, T.A., et al. *Am. J. Cardiol.* 69: 1458-1466, 1992). Based upon molecular evidence of enteroviral involvement, approximately 20-30% of cases of acute inflammatory heart muscle disease and dilated cardiomyopathy involve an enteroviral etiology (see, e.g., Kandolf, R. Coxsackieviruses-A General Update, p. 292-318, 1988; and Martino, T.A., et al., *Circ. Res.* 74:182-188, 1994).

The inflammatory process which characterizes enterovirus-induced inflammatory heart disease has been extensively studied in murine models (reviewed in Gauntt, C., et al., Medical Virology, 8th ed., p. 161-182, 1989; Leslie, K., et al., *Clin. Microbiol. Rev.* 2:191-203, 1989; Sole, M., and P. Liu., *J. Amer. Coll. Cardiol.* 22 (Suppl.A):99A-105A, 1994; and Woodruff, J.F., *Am. J. Pathol.* 101:425-484, 1980), but it remains unclear precisely what specific roles are played by the various components of the cell-mediated immune response in the induction of acute disease and continuation of the chronic state. However, it is clear that in the presence of an intact murine immune system, CVB3-induced inflammatory heart disease develops only following inoculation of mice with a cardiovirulent CVB3 strain (Chapman, N.M., et al., *Arch. Virol.* 135:115-130, 1994; Gauntt, C.J., et al., *J. Med. Virol.* 3:207-220, 1979; Tracy, S., et al., *Arch. Virol.* 122:399-409, 1992; and Woodruff, J.F., and E.D. Kilbourne, *J. Infect. Dis.* 121:137-163, 1970).

Both cardiovirulent (able to induce disease) and non-cardiovirulent strains of CVB3 replicate well in hearts of experimentally-infected mice. Only cardiovirulent CVB3 strains, however, cause the significant cardiomyocyte destruction with subsequent

-4-

cardiac inflammation which is characteristic of acute myocarditis (Chapman, N.M., et al., *Arch. Virol.* 135: 115-130 (1994); and Tracy, S., et al., *Arch. Virol.* 122:399-409, 1992). Non-cardiovirulent CVB3 is cleared
5 from the experimentally-infected murine heart within 7-10 days post-infection, while infectious cardiovirulent CVB3 can remain detectable in hearts for up to 2 weeks post-infection (Klingel, K., et al, *Proc. Natl. Acad. Sci. U.S.A.* 89:314-318, 1992; Lodge, P.A., et al., *Am. J. Pathol.* 128:455-463, 1987; and Tracy, S., et al., *Arch. Virol.* 122:399-409, 1992). The fall in murine cardiac infectious CVB3 titer is coincident with the rise in anti-CVB3 neutralizing antibody titers and the ability of
10 T cells to recognize CVB3 antigens (Beck, M.A., and S. Tracy, *J. Virol.* 63:4148-4156, 1989; Gauntt, C., et al., Medical Virology, 8th ed., p. 161-182, 1989; and Leslie, K., et al., *Clin. Microbiol. Rev.* 2:191-203, 1989). In addition to direct *in situ* hybridization evidence for enteroviral replication in human heart myocytes and for
15 cardiovirulent CVB3 replication in murine heart myocytes, CVB3 infects a variety of cultured cardiac cell types including murine and human cardiomyocytes, murine fetal heart fibroblasts and cardiac endothelial cells.

Of great interest is that heart transplantation
25 and acute enteroviral heart disease evoke a similar immune response in a host. Acute rejection of a transplanted heart involves primarily a Th1 type T cell response, the same type of T cell response that is observed in CVB3 induction of acute myocarditis in
30 well-studied murine models of CVB3-induced inflammatory heart disease. Switching of this response to the Th2 type response, with a concomitant ablation of disease, has been accomplished in mice through parenteral administration of the key modulatory cytokines IL-4 or
35 IL-10. However, parenteral administration of cytokines to humans often results in undesired clinical side effects.

-5-

Thus, the prior art is deficient in the use of an attenuated coxsackievirus as a gene delivery vector, specifically to target immunomodulatory or other biologically active genes or antigenic epitopes to selected cells, tissues or organs, including the heart. Such a mode of administration or gene delivery circumvents the undesirable side effects of parenteral administration of immunomodulatory agents, antigens or other therapeutic molecules. Thus, the present invention fulfills this long-standing need and desire in the art.

SUMMARY OF THE INVENTION

One object of the present invention is to provide viral vectors for therapeutic or prophylactic use in human disease by delivering nucleic acids encoding antigenic epitopes or specific biologically active gene products, such as (but not limited to) immunomodulatory cytokines, to target cells, tissues or organs in an individual.

Thus, according to one aspect of the invention, a viral vector for delivering a heterologous nucleic acid to a target cell, tissue or organ is provided, which comprises a coxsackievirus genome modified to encode an attenuated coxsackievirus, the genome further comprising at least one cloning site for insertion of at least one expressible heterologous nucleic acid. In a preferred embodiment, the coxsackievirus genome is a coxsackievirus B genome, most preferably a coxsackievirus B3 genome.

In one embodiment of the invention, attenuation of the coxsackievirus is achieved by altering a transcription regulatory region of the genome. Preferably, the transcription regulatory region comprises a 5' untranslated region of the genome. In one embodiment, the 5' untranslated region is replaced with a 5' untranslated region of a non-enterovirus genome selected from the group consisting of poliovirus and echovirus. In another embodiment, a coxsackievirus B3

-6-

genome is modified by substituting a C or G for a U at nucleotide position 234 of the genome.

The cloning site of the coxsackievirus vector can be positioned between a coding sequence for a capsid protein and a coding sequence for viral protease. In
5 another embodiment, the cloning site is positioned at the start of the genome's open reading frame, and is constructed such that the inserted expressible heterologous DNA comprises a translation start codon and
10 a 3' sequence recognized by a viral protease.

In one embodiment, the expressible heterologous DNA carried by the coxsackievirus vector of the invention encodes an antigenic product. In another embodiment, it encodes a biologically active product, such as a
15 biologically active protein. Preferably, the protein is a cytokine, such as IL-4 or IL-10. Alternatively, the protein could be another immunomodulatory protein, such as B-7 (B-7-1 or B-7-2).

According to another aspect of the present
20 invention, there is provided a bioengineered virus for the therapeutic delivery of at least one heterologous gene to a target organ or organ system in an individual, comprising a Coxsackievirus B3 (CVB3), wherein said Coxsackievirus B3 is attenuated, and wherein a genome of
25 said CVB3 codes for said at least one heterologous gene. Attenuation of the CVB3 may be accomplished through a transcriptional mechanism. Preferred embodiments include attenuating the virus by substituting a cytosine or guanosine nucleotide for a uracil nucleotide at position
30 nt234 in the genome of the coxsackievirus B3. Another preferred embodiment includes point mutations at positions nt233 and nt236 in the genome of the Coxsackievirus B3, or deletion entirely of nt 233-236.

In addition, the 5' non-translated region of
35 the genome of the Coxsackievirus B3 may be substituted with a 5' non-translated region of a genome from a non-enterovirus to achieve attenuation. In a preferred

-7-

embodiment, the non-enterovirus is a poliovirus or echovirus.

In most preferred embodiments, the genome of the bioengineered Cocksackievirus B3 includes the basic
5 CVB3/0 genome (as reported by Chapman, N.M., et al, Arch. Virol. 135: 115-130 (1994)), wherein a coding sequence for a heterologous gene is inserted between a capsid protein coding sequence and a viral protease coding region site. Alternatively, a heterologous gene may be
10 inserted at the start of the open reading frame, directly upstream of capsid protein 1A, start with the initiation codon AUG, and end with a sequence recognized by a viral protease. In this preferred embodiment, an immunomodulatory gene or a gene for an antigenic epitope
15 is used. In a more preferred embodiment, cytokine genes are delivered. In a most preferred embodiment, the cytokine is IL-4 or IL-10. Up to seven cytokine genes may be delivered in one vector. Further, both antigenic epitopes and cytokines may be delivered at the same time.
20 Also, a preferred embodiment utilizes sequences for viral proteases P2-A and P3-C.

A further object of the present invention is to provide a method for suppressing an immune response in an individual, comprising the step of administering the
25 bioengineered therapeutic virus containing an immunomodulatory gene to an individual.

An additional object of the present invention is to provide a method for vaccinating an individual, comprising the step of administering the bioengineered
30 therapeutic virus containing a gene for an antigenic epitope to an individual.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred
35 embodiments of the invention. These embodiments are given for the purpose of disclosure.

-8-

BRIEF DESCRIPTION OF THE DRAWINGS

The appended drawings have been included herein so that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These drawings form a part of the specification. The appended drawings illustrate preferred embodiments of the invention and should not be considered to limit the scope of the invention.

Figure 1 shows the mIL4 insert in the CVB3/0-IL4 genome. The mIL4 sequence has been cloned between the viral capsid protein P1-D and the viral protease 2A (P2-A). During translation of the viral polyprotein, the most likely mechanism is that the protease P2-A cleaves itself out of the nascent protein in cis and cleaves the site between the capsid protein PI-D and mIL4 sequence in trans.

Figure 2 shows the amino acid sequence of the PLS-CVB3 genome and the mIL-10-CVB3 at the site of the protease 2A cleavage. In this construct, the cloning procedure has been modified to include a polylinker site (PLS) to facilitate the use of the CVB3 as a generic cloning and expression vehicle. Further modifications include non-direct repeat genetic sequences to code for the protease P2-A cleavage site in the nascent polyprotein. The amino acids donated by the PLS are underlined, while the amino acids which form the 2A cleavage recognition signal are double underlined. The sequence of the mIL-10 insertion is shown in bold.

Figure 3 shows the nucleotide and amino acid sequence of the PLS-CVB3 genome and mIL-10-CVB3 genome at the beginning of the open reading frame. In this construct, the foreign or heterologous sequence is cloned in the open reading frame upstream of the first encoded viral protein. The translational initiation thus occurs at the beginning of the mIL10 sequence (or other sequence of interest). This construct employs either the viral protease 3C to cleave the foreign protein, here modeled

-9-

as mIL10, from the first viral capsid protein P1-A. The nucleotide and amino acid sequence of the PLS are underlined and the protease 3C recognition site is double underlined. The sequence of the mIL-10 insertion is shown in bold.

Figure 4 shows the structure of the CPV/49-Polylinker genome.

Figure 5 shows the results of a slot blot of total RNA from HeLa cells inoculated with sequential passages of CVB3/0-IL4 and probed with (left) an mIL4-specific oligonucleotide or (right) a CVB3-specific oligonucleotide. After transfection of the pCVB3/0-IL4 cDNA into HeLa cells and obtaining progeny virus, a stock was made in HeLa cells (pass 1). The stock was used to inoculate a 100mm dish of HeLa cells at an MOI of 20 (pass 2). After titering, pass 2 was used to inoculate new HeLa cells (pass 3), and so on. To obtain RNA for these experiments, passes 1-5 were used to inoculate a nearly confluent 100mm dish of HeLa cells at an MOI of 20. Cells were washed after 1 hour, and harvested 5 hours post-infection. Total nucleic acids were digested with DNase. The equivalent of 2×10^5 and 0.4×10^5 cells were blotted for each passage. The same mass of oligonucleotide probe with equivalent specific radioactivities were used for each strip. Control blots using an alpha-tubulin probe demonstrated each RNA concentration used to be equivalent; RNase treatment of control blots demonstrated no RNA or DNA was detectable.

Figure 6 shows histologic thin sections of murine pancreatic tissue following infection of mice either by CVB3/0 (left-hand panel) or CVB3/0-IL4 (right-hand panel). Mice were sacrificed on day 10 post-infection. CVB3/0 induces severe pancreatic acinar cell destruction; intact acinar cells can be seen in lower right hand corner of the panel. CVB3/0-IL4 does not induce any observable pathologic changes in the murine pancreas (right hand panel).

-10-

DETAILED DESCRIPTION OF THE INVENTION

It will be apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

As used herein, the term "Coxsackie B3 virus;" or "CVB3" refers to a specific serotype of the human coxsackie B enterovirus of the family *Picornaviridae*, genus *Eterovirus*. The CVB3 genome is characterized by a single molecule of positive sense RNA which encodes a 2,185 amino acid polyprotein.

As used herein, the term "cardiotropic" refers to the targeting of heart tissue by a virus, in this case Coxsackievirus B3.

As used herein, the term "attenuated" refers to a virus, in this case Coxsackievirus B3, that is engineered to be less virulent (disease-causing) than wildtype Coxsackievirus B3.

As used herein, the term "one way viral vector" refers to viral delivery vehicles which are replication deficient for virus production but the RNA genomes of which can autonomously replicate in infected cells for variable periods of time. Such a vector permits replacement of essentially all of the capsid coding region with other sequences of interest, potentially delivering as many as seven cytokine-size coding sequences in the viral genomes. Such genomes made defective through deletion of a polymerase sequence and under a mammalian promoter may be used as a vector for a DNA vaccine or therapeutic, to be delivered by standard means, such as injection or oral administration.

As used herein, the term "basic CVB3/0 genome" shall mean the bioengineered Coxsackievirus B3 as reported by Chapman, N.M., et al, *Arch. Virol.* 122:399-409 (1994).

As used herein, the term "viral protease" or "viral encoded protease" refers to viral encoded enzymes

-11-

that degrade proteins by hydrolyzing peptide bonds between amino residues. Some such proteases recognize and cleave at only specific sequences.

As used herein, the term "immunomodulatory gene" refers to a gene, the expression of which modulates the course of an immune reaction to a specific stimulus or a variety of stimuli. Examples include interleukin 4, interleukin 10, tumor necrosis factor α , etc.

As used herein, the term "cytokine" refers to a small protein produced by cells of the immune system that can affect and direct the course of an immune response to specific stimuli.

As used herein, the term "antigenic epitope" refers to a sequence of a protein that is recognized as antigenic by cells of the immune system and against which is then directed an immune response, such as an antibody response, for example.

As used herein, the term "viral vector" refers to a virus that is able to transmit foreign or heterologous genetic information to a host. This foreign genetic information may be translated into a protein product, but this is not a necessary requirement for the foreign information.

As used herein, the term "open reading frame" refers to a length of RNA sequence, between an AUG translation start signal and any one or more of the known termination codons, which can be translated potentially into a polypeptide sequence.

As used herein, the term "capsid coding region" refers to that region of a viral genome that contains the DNA or RNA code for protein subunits that are packaged into the protein coat of the virus particle.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook et al., "Molecular

-12-

Cloning: A Laboratory Manual (1989); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984); or "Current Protocols in Molecular Biology", eds. Frederick M. Ausubel et al., John Wiley & Sons, 1997.

Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "vector" is a replicon, such as plasmid, phage, cosmid, or virus to which another DNA or RNA segment may be attached so as to bring about the replication of the attached segment. A vector is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient mammal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a change in the physiology of a recipient mammal. For example, in the treatment of retroviral infection, a compound which decreases the extent of infection or of physiologic damage due to infection, would be considered therapeutically effective.

An "origin of replication" refers to those DNA sequences that participate in the in the initiation of DNA synthesis.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and

-13-

initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends
5 upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined by mapping with nuclease S1), as
10 well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35
15 consensus sequences.

An "expression control sequence" is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is "under the control" of transcriptional and
20 translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

A "signal sequence" can be included before the
25 coding sequence.

As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.

30 A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells
35 for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in

-14-

which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to
5 establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis. A "cell line" is a clone of a primary cell that is capable of stable growth
10 in vitro for many generations.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region
15 encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA
20 where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.

25 The present invention provides a viral vector for delivering a heterologous nucleic acid to a target cell, tissue or organ, which comprises a coxsackievirus genome modified to encode an attenuated coxsackievirus. The genome further comprises at least one cloning site
30 for insertion of at least one expressible heterologous nucleic acid. Although in a preferred embodiment, the coxsackievirus genome is a coxsackievirus B genome, most preferably a coxsackievirus B3 genome, any coxsackievirus genome is believed to be suitable for use in the present
35 invention. This is due to the high level of organizational similarity among the coxsackieviruses, and indeed among enteroviruses in general (see, e.g., Romero

-15-

et al., *Current Topics in Microbiology and Immunology* 223: 97-152, 1997, reviewing the genetic relationship among the Group B coxsackieviruses; Chapman et al., *Current Topics in Microbiology and Immunology* 223: 227-
5 258, 1997, reviewing the genetics of coxsackievirus virulence; and Tracy et al., *Trends in Microbiology* 4: 175-179, 1996, reviewing the genetics of coxsackievirus B (cardiovirulence and inflammatory heart muscle disease). Thus, in the present invention it has been demonstrated
10 that CVB3 can be attenuated by manipulation of the genome in a variety of ways, most of them relating to altering a transcription regulatory region of the genome, such as the 5' untranslated region of the genome. These alterations are described in greater detail below, and in
15 the examples. Similar manipulations likewise can be made to attenuate any of the other five coxsackievirus B serotypes, as well as coxsackievirus A or other enteroviruses.

It has also been demonstrated in accordance
20 with the present invention that a heterologous DNA segment can be inserted in the CVB3 genome in one of several locations, e.g., between a coding sequence for a capsid protein and a coding sequence for viral protease, or at the start of the genome's open reading frame, in
25 such a manner that the heterologous DNA comprises a translation start codon and a 3' sequence recognized by a viral protease. These insertions are described in greater detail below, and in the Examples. Similar insertions likewise can be made in the genomes of the
30 other coxsackieviruses or other enteroviruses, and successful expression of these heterologous nucleic acids also is expected. Moreover, one skilled in the art also will appreciate that other useful insertion sites exist and can be exploited in the coxsackievirus genome.

35 Concerning the size of the heterologous nucleic acid that can be inserted into a coxsackievirus vector of the invention, it has been discovered that the genome can

-16-

incorporate an insert encoding up to 200-400 amino acids. The size of the insert may be increased (e.g., to inserts encoding 800-1,000 amino acids), if certain portions of the genome (e.g., capsid protein coding sequences) are
5 deleted. In this embodiment, it would be necessary to supply a helper virus to provide the missing capsid proteins in trans, for packaging the virus. Such manipulations of viral vectors are well known to persons skilled in the art.

10 The heterologous nucleic acid sequence carried by the coxsackievirus vector of the invention can encode any gene product, including RNA of any kind, peptides and proteins. In one embodiment, the expressible heterologous DNA carried by the coxsackievirus vector of
15 the invention encodes an antigenic product. In another embodiment, it encodes a biologically active product, such as a biologically active protein. Preferably, the protein is a cytokine, such as IL-4 or IL-10, as described in greater detail below and in the examples.

20 Particularly preferred aspects of the present invention are directed to a bioengineered virus for the therapeutic delivery of at least one heterologous gene to a target organ or organ system in an individual, comprising a Coxsackievirus B3, wherein said
25 Coxsackievirus B3 is cardiotropic and attenuated, and wherein the genome of the CVB3 codes for the at least one heterologous gene.

It is contemplated additionally that the present invention provides (1) a method for suppressing
30 an immune response in an individual, comprising administering the coxsackievirus vector containing an immunomodulatory gene to an individual and (2) a method for vaccinating an individual, comprising administering a coxsackievirus containing a gene for an antigenic epitope
35 to an individual.

For gene delivery applications, a person having ordinary skill in the art of molecular biology, gene

-17-

therapy and pharmacology would be able to determine, without undue experimentation, the appropriate dosages and routes of administration of the novel coxsackievirus gene delivery vector of the present invention.

5 One specific object of the present invention is to use artificially attenuated cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease. The invention encompasses reducing, or ablating entirely, heart transplant rejection through therapeutic use of immunosuppressive cytokines delivered by attenuated cardiotropic virus vectors. The invention is equally applicable to other inflammatory diseases or conditions of a variety of organs. In this aspect, the invention thus requires three elements: First, an attenuated CVB3 viral vector must be provided. Second, the CVB3 viral vector must be able to express an immunomodulatory protein, such as a cytokine. Third, the vector must be able to deliver the immunomodulatory protein to the target tissue and observably reduce disease symptoms. These three elements are provided in the present invention. Cardiovirulence of CVB3 has been reduced to complete attenuation for heart disease by the substitution of the entire 5' NTR with that of a non-coxsackie enterovirus. The murine cytokine IL-4 (mIL-4) has been expressed within the open reading frame of an attenuated CVB3 strain and has been demonstrated to be biologically active. Inoculation of the CVB3 chimera expressing mIL-4 into mice 1 or 3 days post-inoculation with a pancreovirulent CVB4 strain significantly ablates CVB4-induced pancreatic disease. These data exemplify the unique therapeutic approach to inflammatory diseases of the present invention, and are described in detail in the examples that follow.

-18-

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit it in any fashion.

5

EXAMPLE 1
Artificial attenuation of CVB3
for cardiac disease in mice

It has been demonstrated that 5' NTRs of related enteroviruses could be exchanged and viable progeny virus produced when a poliovirus type 1 5' NTR was replaced with some or all of a CVB3 5' NTR (Johnson V.H., and B.L. Semler, *Virology* 162(1):47-57 (1988); and Semler B.L., et al., *Proc-Natl Acad Sci USA* 83(6): 1777-81 (1986)). For the present invention, a variety of CVB3 strains with genomes chimeric in the 5' and/or 3' non-translated regions (NTR) sequences has been constructed from poliovirus type 1. The construct that consists of the 5' NTR from PV1/Mahoney and the remainder of the genome from CVB3/20 has been used most extensively in the investigation of the current invention.

Five passages of this chimeric virus, CPV/49 (Figure 4), did not result in genetic alteration in the donated poliovirus 5' NTR on the basis of sequence analysis. Replacement of a cardiovirulent CVB3 5' NTR with the homolog from the neurovirulent PV1 Mahoney strain results in a progeny virus that is (a) genetically stable in cell culture in terms of maintaining the PV sequence of the 5' NTR; and (b) highly attenuated for its ability to induce myocarditis in mice, and replicates to 3-4 logs lower titer in the murine heart relative to the parental cardiovirulent CVB3/20 strain. Notwithstanding this attenuation, antibody titers are induced against CVB3 in the inoculated mice that prevent cardiac disease when the mice are challenged with inoculation by a cardiovirulent CVB3 strain.

These data demonstrate that a CVB3 virus strain made chimeric with the replacement of the 5' NTR from PV1 results in a CVB3 strain that is stably attenuated for

-19-

heart disease when measured in mice and animals, and, furthermore, acts as a vaccine strain by preventing heart disease due to challenge by cardiovirulent CVB3 infection. Thus, such a virus strain acts as a delivery
5 system as envisioned in the present invention.

In addition, the mechanism by which a non-cardiovirulent CVB3 strain (CVB3/0) is attenuated for cardiovirulence has been mapped and identified. By comparison of the complete nucleotide sequences of the
10 avirulent and cardiovirulent CVB3 strains and analyzing a series of intratypic chimeric viruses designed to test the potential genetic sites, a single site nt234 was demonstrated to be the sole site that affected cardiovirulence in these virus strains (Tu Z., et al., *J Virol* 69:4607-18(1995)). The nt234 is U in the
15 cardiovirulent strain, and C in the avirulent strain. Assay in murine heart cells demonstrated little or no detectable differences in Western blotted viral proteins between the two strains, but at least a ten-fold
20 disparity in viral RNA transcription rate was identified. Further work has shown that the normally high positive to negative viral RNA strand ratio in infected cells is significantly altered to near unity when nt234 is C rather than U.

Two further observations make it clear that alteration of certain 5' NTR sequences results in attenuation. One is that mutation of nt234U to G also results in attenuation by what appears to be a similar mechanism to that observed for nt234 C. Second, mutation
30 of this same nucleotide to G in PVL/Mahoney also results in a strain of virus that grows less robustly in HeLa cells than the parental virus. Because nt234 is conserved as U in all enteroviral RNAs examined so far (Chapman N.M., et al., *J. Med. Virol.* 52: 258-261, 1997), as are
35 the surrounding 5 nucleotides 5'-CGUUA (nt234 is underlined), mutation at this site appears to be generally deleterious for enterovirus health. A CVB3

-20-

strain, chimeric in the 5' NTR using the PV1 sequence with the added mutation of G instead of U at the PV equivalent of nt234 provides a stably attenuated (but possibly quite weak) CVB3 strain, even less prone to reversion to cardiovirulence than the stably attenuated CVB3/PV1 chimeric described above. Either of these chimeric CVB3 strains is suitable for the viral delivery vector of the present invention in which murine interleukins are expressed within the open reading frame of an artificially attenuated CVB3 strain.

EXAMPLE 2

Successful expression of biologically active murine IL - 4 from within the CVB3 Open Reading Frame

One viral vector construct envisioned by the present invention is depicted in Figure 1. Acute rejection of a transplanted heart involves primarily a Th1 type T cell response, the same type of T cell response that is observed in CVB3 induction of acute myocarditis in well-studied murine models of CVB3-induced inflammatory heart disease. Switching of the response to the Th2 type response causes a concomitant ablation of disease. Due to the interest in increasing Th2 type responses, expression of the murine IL-4 gene (mIL-4) was chosen. The virus vector used was the infectious cDNA clone of CVB3/0, a CVB3 strain effectively attenuated for murine heart disease through the mutation at nt234 (from U to C). The mIL-4 sequence contained the signal sequence to facilitate extracellular transport of the expressed interleukin protein (see Sideras P., et al., *Adv Exp Med Biol* 213:227-23.6 (1987)). Flanking the mIL-4 insert were cloned identical sequences that are recognized by the CVB3 protease 2A. The mIL-4 insert plus the flanking sequences encoding the protease 2A recognition cleavage sites were cloned in-frame at the junction of the capsid protein 1D and protease 2A.

The construct gave rise to progeny virus

-21-

(termed CVB3/0-IL4) when electroporated into HeLa cells. Sequence analysis by reverse-transcriptase mediated PCR followed by sequence analysis of the amplicon confirmed that the progeny virus contained the insert and that the viral open reading frame was maintained. The mIL-4 coding sequence in the viral RNA was detected readily by slot blot analysis through 5 passages in HeLa cells, after which deletion occurs rapidly (Figure 5). This is most likely due to recombination in the 72 nucleotide direct repeat that was engineered to duplicate the protease 2A cleavage sites (see Figure 1). This is not unexpected: once a CVB3/0 genome deletes the mIL-4 coding sequence, it would be expected to replicate more rapidly, and would rapidly become the dominant quasi species. This may be reflected in the blot following the CVB3 RNA as well: later passages suggest slightly more viral RNA present in the samples.

That the strain CVB3/0-IL4 expressed murine IL-4 in HeLa cells was confirmed by ELISA. Virus was inoculated onto HeLa cells, excess virus was removed by washing at one hour post infection, and the cells were re-fed. At times post-inoculation, the supernatant was removed and then the cells were frozen in a similar volume of fresh medium. Following freezing and thawing and removal of cell debris by centrifugation, the cell medium samples, and the cell fractions were assayed using a commercially available ELISA test for murine IL-4 (BioSource International, Inc.). CVB3/0-IL4 produced mIL-4 intracellularly well above the uninfected control background, reaching 300 pg/ml by 6 hours in cultures producing 10^6 TCID₅₀ units of virus/ml.

Biological activity of the CVB3/0-IL4 expressed murine IL-4 was assessed using supernatants from HeLa cells infected with the virus, washed with media, incubated for 6-8 hours, then frozen and thawed. Supernatants cleared of cellular debris were assayed for ability to induce MC/9 mouse mast cells to proliferate

-22-

using an MTT assay (Mosmann T., *J Immunol Methods* 65(1-2):55-63 (1983); and Gieni S, et al., *J Immunol Methods* 187(1):85-93 (1995)) with recombinant mIL-4 as standard. CVB3/0-IL4 HeLa cultures produced 3 units/ml (equivalent to 250 pg/ml of recombinant mIL-4). This compares favorably with reported IL-4 levels in coronary sinus blood concentrations in cardiac transplant patient (229 pg/ml; Fyfe A, et al., *J Am Coll Cardiol* 21(1):171-6 (1993)).

To date, these are the sole data that demonstrate that an interleukin has been cloned successfully in and expressed within the open reading frame of an enterovirus.

15

EXAMPLE 3**Diminution of CVB4-induced pancreatic disease in mice by treatment with mIL-4 expressing CVB3**

In an initial test of the ability of the CVB3-IL4 strain to decrease inflammatory disease induced by enteroviruses, a virulent CVB4 strain was used as the inflammatory disease inducer. A different CVB serotype was chosen to minimize the possibility that neutralizing antibodies might reduce the replication of CVB3-IL4 in the doubly-infected mouse (Beck M., et al., *Am. J. Pathol.* 136:669-681 (1990)). The strain of CVB4, termed CVB4-V, was derived by repeated passaging in mice of the avirulent strain, CVB4/P until the virus was repeatedly able to induce severe destruction of the murine pancreatic acinar cells (Ramsingh A., et al, *Virus Res* 23(3):281-92 (1992)). The pancreatic disease induced by this virus is likely to have an immune component based on the lack of correlation between virulence and the extent of virus replication in the pancreas and the dependence upon host genetic background. Further, it has been demonstrated that CVB4/V is also pancreovirulent in C3H/HeJ male mice, the mice routinely employed to study CVB3 inflammatory heart disease (see Kiel R.J., et al., *European Journal of Epidemiology* 5:348-350 (1989)). In

-23-

order to determine whether CVB3/0-IL4 would have an effect upon pancreatic disease induced by this strain of CVB4, the experiment outlined in Table 1 was performed.

5 **Table 1: OUTLINE OF CVB4/CVB3 EXPERIMENT AND RESULTS IN DISEASE/TOTAL PANCREASES OBSERVED AT DAY 10 PI**

	DAY 0 INOC.	DAY 1 INOC.	DAY 3 INOC.	NUMBER OF MICE	DAY 10 PANCREATIC DISEASE
10	MEDIUM	NONE	NONE	3	NONE (3)
	CVB3/0	NONE	NONE	4	SLIGHT (1)
					SEVERE (3)
15	CVB3/0-IL4	NONE	NONE	8	NONE (7)
					SLIGHT (1)
	CVB4/V	NONE	NONE	5	SEVERE (5)
	CVB4/V	CVB 3/0	NONE	5	MODERATE (1)
					SEVERE (4)
20	CVB4/V	NONE	CVB3/0	4	SEVERE (4)
	CVB4/V	CVB3/0-IL4	NONE	9	SLIGHT (2)
					MODERATE 5
					SEVERE (2)
25	CVB4/V	NONE	CVB3/0-IL4	10	SLIGHT (2)
					MODERATE (4)
					SEVERE (4)

Briefly, mice were inoculated with 5×10^5 TCID₅₀ units of CVB4/V in 0.1 ml unsupplemented medium. One or three days later, mice were also inoculated with an equivalent dose of CVB3/IL4 (second passage virus stock after transfection). Control mice were inoculated with the parental (without IL-4 insert and 2A-cleavage site insert) CVB3/0 at the same times. In addition, mice were inoculated with unsupplemented medium without virus or with a single virus: CVB3/IL4, CVB4/V, or CVB3/0. On day 10 post-infection, pancreata were fixed in formalin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Examples of the type of pathologies observed are shown in Figure 6.

All the mice inoculated only with CVB4/V incurred massive pancreatic damage (Table 1). Mice

-24-

inoculated with CVB4/V, and that subsequently received
CVB3/0-IL4 either on day 1 or day 3 post-infection,
demonstrated a significant ablation in the extent of
disease. No significant difference was observed between
5 pancreas tissue from mice with day 1 or day 3
post-infection (post CVB4/V) inoculation with CVB3/0-IL4.
Mice that were inoculated with CVB4/V and subsequently
inoculated with the attenuated parental CVB3/0 strain at
either day 1 or 3, demonstrated pancreata that were
10 indistinguishable from the CVB4/V only mice. Thus, the
diminution of pancreatic damage observed in mice that
received first pancreovirulent CVB4/V, then CVB3/0-IL4 on
day 1 or 3 post infection, is due to the expression of
the mIL-4 in the chimeric CVB3 strain.

15 In addition, the CVB3/0-IL4 construct was not
virulent for the pancreas. Even though CVB3/0 is
completely attenuated for heart disease, it causes
significant and widespread destruction of the murine
acinar cells. While mice that received only CVB3/0
20 demonstrated significant pancreatic damage, it is worth
noting that the presence of the mIL-4 coding sequence in
the CVB3/0 genome resulted in a virus which did not
induce pancreatic disease in mice. These data, combined
with the data above that showed a diminution of
25 CVB4-caused pancreatic disease by administration of the
CVB3/0-IL4 chimera, are consistent with a beneficial role
upon pancreatic disease diminution caused by an
enterovirus.

30

35

-25-

EXAMPLE 4
Attenuation of Coxsackievirus B3 Replication by
Two Point Mutations in the 5' Non-translated Region

5 In Example 1 we described a conserved 5-
nucleotide region, surrounding nt234 of the CVB3 genome,
that appears important for replication of the enterovirus
genome. In this Example, the molecular grounds for the
complete conservation of that 5'-CGUUA (nt 232-236) in
10 the enteroviral 5' non-translated region are examined.
Using the well-characterized enterovirus model system,
CVB3, point mutations were created at nt233 (G→C) and
nt236 (A→U) in the CVB3 5' non-translated region using
site specific mutagenesis, according to standard
15 methodology. This double mutant (pCVB3-88) was
electroporated into HeLa cells and the progeny virus
(CVB3/88) was passaged six consecutive times in HeLa
cells. Virus from each passage was assayed in single-
step growth curves and by nucleotide sequence analysis.

20 Prior to passage 3, CVB3/88 was highly
attenuated, generating barely detectable titers. Passage
3 CVB3/88 entered log phase replication 3 hours later and
achieved final titer 100 fold lower than the parental
(control) CVB3 strain. Passage 4 showed an improved rate
25 of replication and final titer 10 fold lower than the
parental virus. CVB3/88 passage 5 replication was
essentially indistinguishable from the parental strain.

30 Direct sequence analysis of CVB3/88 RNA using
RT-PCR demonstrated that complete reversion had occurred
by passage 5, whereas passage 4 virus indicated a partial
reversion at nt233(G/C) and complete reversion at nt236
(U→A). Passage 3 showed partial reversion at both sites.

35 Reacquisition of wild-type replication rate and
efficiency is directly correlated with reversion of the
mutations to wild-type sequence. The degree of initial
attenuation, and concomitant rapidity of reversion argues
against robust compensatory mutations arising elsewhere
in the viral genome, and is consistent with the previous
evidence that this 5 nucleotide tract is absolutely

-26-

conserved for efficient enteroviral replication.

It should be noted that live, attenuated viruses are useful as vaccines or gene delivery vehicles even if they revert to wild-type through several passages in cultured cells. In fact, live attenuated polioviruses exhibit reversion to wild-type, and these have been used as highly successful oral vaccines for many years. The risk of reversion after a single administration to a living individual (as opposed to several passages in cultured cells) is low, due to the fact that a normal individual will mount an immune response to the virus and clear it from the system before it has the opportunity to replicate to pathogenic levels in a critical target tissue (e.g., neurons). As a result, live, attenuated poliovirus is an effective vaccine even though it reverts to wild-type after passaging through culture cells. Likewise, forms of live, attenuated coxsackievirus and other enteroviruses that may revert to wild-type in culture still will be effective and useful for a variety of purposes. Less reversion-prone viruses, such as the CPV/49 described in Example 1, could be used for purposes where a reversion-prone attenuated virus is inappropriate.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds

-27-

described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

5

-28-

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANTS: Tracy, Steven M.; Chapman, Nora M.; Kolbeck, Peter; and Malone, James
- 5 (ii) TITLE OF INVENTION: COXSACKIE VIRUS VECTORS FOR DELIVERY OF NUCLEIC ACIDS ENCODING ANTIGENIC OR THERAPEUTIC PRODUCTS
- (iii) NUMBER OF SEQUENCES: 8
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Dann, Dorfman, Herrell & Skillman, P.C.
- 10 (B) STREET: 1601 Market Street, Suite 720
- (C) CITY: Philadelphia
- (D) STATE: Pennsylvania
- (E) COUNTRY: USA
- (F) ZIP: 19103
- 15 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM compatible
- (C) OPERATING SYSTEM: MS-DOS
- (D) SOFTWARE: Wordperfect 6.1
- 20 (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER: Not yet assigned
- (B) FILING DATE: 5 March, 1998
- (C) CLASSIFICATION:
- 25 (vii) RELATED APPLICATION DATA
- (A) APPLICATION NUMBER: US 08/812,121
- (B) FILING DATE: 5 March, 1997
- 30 (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Reed, Janet E.
- (B) REGISTRATION NUMBER: 36,252
- (C) REFERENCE/DOCKET NUMBER: UNMC.63116PCT
- 35 (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: 215-563-4100
- (B) TELEFAX: 215-563-4044
- (2) INFORMATION FOR SEQ ID NO: 1:
- 40 SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 85 bp
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 45 (D) TOPOLOGY: linear

-29-

- (ii) MOLECULE TYPE:
(A) Description: other nucleic acid
(iii) HYPOTHETICAL: No
(iv) ANTISENSE: No
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
ATCACTACAA TGACAAATAC GGGCGCATTT GGACAACAAT CAAGGGGCAG CGTATGTGGG 60
GAACTACAGG GTAATGGGTC TCAAC 85
- 10 (3) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 80bp
(B) TYPE: nucleic acid
15 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) Description: other nucleic acid
(iii) HYPOTHETICAL: No
20 (iv) ANTISENSE: No
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
TACTCGATCA CTACAATGAC AAATACGGGC GCATTTGGAC AACATCAGG GGCAGCGTAT 60
GTGGGGAACT ACAGGGTAGT 80
- 25 (4) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 residues
30 (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE:
35 (A) Description: protein
(iii) HYPOTHETICAL: No
(iv) ANTISENSE: No
(vi) ORIGINAL SOURCE:
- 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Ser Gly Val Thr Thr Thr Arg Gln Ser Ile Thr Thr Met Thr Asn 15
Thr Gly Ala Phe Gly Gln Gln Ser Gly Ala Val Thr Leu Glu Met 30
Pro Gly Ser Ala 34
- 45

-30-

(5) INFORMATION FOR SEQ ID NO:4

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 residues

(B) TYPE: amino acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

(A) Description: protein

(iii) HYPOTHETICAL: No

10 (iv) ANTISENSE: No

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Lys Ser Asn Ser Ile Thr Thr Met Thr Asn Thr Gly Ala Phe 15

15 Gly Gln Gln Ser Gly Ala Val Tyr Val Gly 25

(6) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 27 bp

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

25 (A) Description: other nucleic acid

(iii) HYPOTHETICAL: No

(iv) ANTISENSE: No

(vi) ORIGINAL SOURCE:

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATGGGAAATT CGAGCTCGAT GCCTGGC 27

(7) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 28 bp

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE:

40 (A) Description: other nucleic acid

(iii) HYPOTHETICAL: No

(iv) ANTISENSE: No

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

45 ATGAAAAGCG CATGCGGGT TTCAAGGT 28

-31-

- (8) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 74 bp
- 5 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE:
- (A) Description: other nucleic acid
- 10 (iii) HYPOTHETICAL: No
- (iv) ANTISENSE: No
- (vi) ORIGINAL SOURCE:
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7
- 15 ACTACTAGGC AAAGCATCAC TACAATGACA AATACGGGCG CATTGGACA ACAATCAGGG 60
CAGTCTCGGA TCCA 74
- (9) INFORMATION FOR SEQ ID NO:8:
- 20 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 62bp
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE:
- (A) Description:
- (iii) HYPOTHETICAL: No
- (iv) ANTISENSE: No
- (vi) ORIGINAL SOURCE:
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8
- GAATTCTGCA GATCAATTAC CACCATGACC AACACGGGGC GCATTGGAC AATCAGGGGC 60
AG 62

-32-

WHAT IS CLAIMED IS:

1. A viral vector for delivering a heterologous nucleic acid to a target cell, tissue or organ, which comprises a coxsackievirus genome modified to encode an attenuated coxsackievirus, said genome further comprising at least one cloning site for insertion of at least one expressible heterologous nucleic acid.
2. The vector of claim 1, wherein the coxsackievirus genome is a coxsackievirus B genome.
3. The vector of claim 2, wherein the coxsackievirus genome is a coxsackievirus B3 genome.
4. The vector of claim 3, wherein the coxsackievirus genome is modified by altering a transcription regulatory region of the genome.
5. The vector of claim 4, wherein the transcription regulatory region comprises a 5' untranslated region of the genome.
6. The vector of claim 5, wherein the 5' untranslated region is replaced with a 5' untranslated region of a non-enterovirus genome selected from the group consisting of poliovirus and echovirus.
7. The vector of claim 5, wherein a uracil nucleotide at position 234 of the genome is replaced by a cytosine nucleotide or a guanine nucleotide.
8. The vector of claim 5, wherein a guanine nucleotide at position 233 of the genome is replaced by a cytosine nucleotide and an adenine nucleotide at position 236 of the genome is replaced by a uracil nucleotide.

-33-

9. The vector of claim 1, wherein the cloning site is positioned between a coding sequence for a capsid protein and a coding sequence for viral protease.

5 10. The vector of claim 1, wherein the cloning site is positioned at the start of the genome's open reading frame, and is constructed such that the inserted expressible heterologous DNA comprises a translation start codon and a 3' sequence recognized by a viral
10 protease.

 11. The vector of claim 1, wherein the expressible heterologous DNA encodes an antigenic product.
15

 12. The vector of claim 1, wherein the expressible heterologous DNA encodes a biologically active product.

20 13. The vector of claim 12, wherein the biologically active product is a protein.

 14. The vector of claim 13, wherein the protein is a cytokine.
25

 15. A bioengineered virus for therapeutic delivery of at least one heterologous gene to a target organ or organ system in an individual, comprising a Cocksackievirus B3, wherein said coxsackievirus B3 is
30 attenuated, and wherein a genome of said CVB3 contains a coding region for said at least one heterologous gene.

 16. The bioengineered virus of claim 15, wherein said Cocksackievirus B3 is attenuated through a
35 transcriptional mechanism.

 17. The bioengineered virus of claim 16,

-34-

wherein said genome of said Cocksackievirus B3 comprises a basic CVB3/0 genome, wherein said coding sequence for said heterologous gene is inserted between a capsid protein coding sequence and a viral protease coding region site.

18. The bioengineered virus of claim 16, wherein said genome of said Cocksackievirus B3 comprises a basic CVB3/0 genome, wherein said coding sequence for said heterologous gene is inserted directly upstream of capsid protein 1A, starts with the initiation codon AUG, and ends with a sequence recognized by a viral protease.

19. The bioengineered virus of claim 15, wherein a cytosine nucleotide is substituted for a uracil nucleotide at position nt234 in said genome of said Cocksackievirus B3.

20. The bioengineered virus of claim 15, wherein a guanosine nucleotide is substituted for a uracil nucleotide at position nt234 in said genome of said Cocksackievirus B3.

21. The bioengineered virus of claim 15, wherein a 5' non-translated region of said genome of said Cocksackievirus B3 is substituted with a 5' non-translated region of a genome from a non-enterovirus.

22. The bioengineered virus of claim 21, wherein said non-enterovirus is selected from the group consisting of poliovirus and echovirus.

23. The bioengineered virus of claim 15, wherein said genome of said Cocksackievirus B3 includes one or more sequences selected from the group of SEQ ID No:1, SEQ ID No:2, SEQ ID No:5, SEQ ID No:6, SEQ ID No:7 or SEQ ID No:8.

-35-

24. The bioengineered virus of claim 15, wherein a capsid coding region of said genome of said Coxsackievirus B3 has been replaced with at least one heterologous gene.

5

25. The bioengineered virus of claim 15, wherein said at least one heterologous gene is an immunomodulatory gene.

10

26. The bioengineered virus of claim 25, wherein said immunomodulatory gene is a cytokine.

27. The bioengineered virus of claim 26, wherein said cytokine is selected from the group consisting of IL-4 and IL-10.

15

28. The bioengineered virus of claim 15, comprising up to seven cytokine genes.

20

29. The bioengineered virus of claim 15, wherein said at least one heterologous gene encodes an antigenic epitope.

30. The bioengineered virus of claim 15, comprising a heterologous immunomodulatory gene and a heterologous gene encoding an antigenic epitope.

25

31. A method for suppressing an immune response in an individual, comprising the step of administering the bioengineered virus of claim 25 to an individual.

30

32. A method for vaccinating an individual, comprising the step of administering the bioengineered virus of claim 29 to an individual.

35




FIGURE 1

2/6

CVB3 aa 836 (1D)

PLS

CVB3 aa 864 (2A)

...SGVTTTQSITTMINT/GAFGOOSGAVTLEDPRVPSSNSITTMINT/GAFGOOSGAVYVG...

mIL-10 (1-212)

...SGVTTTQSITTMINT/GAFGOOSGAVTLEMPGSA...MKSNSITTMINT/GAFGOOSGAVYVG...

FIGURE 2

3/6

CVB3 N743

...ATGGGAAATTCGAGCTCGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCGGGTTTTCAAGGA...
...M G N S S S V P G D P L E S T C R H A G E Q / G ...

CVB3 N746


CVB3 aa2 (1A)

mIL-10 (1-212)

...ATGGGAAATTCGAGCTCGATGCCTGGC...ATGAAAAGCGCATGCGGGTTTTCAAGGT
M G N S S S M P G ... M K S H A G E Q / G

FIGURE 3

4/6



* indicates position in which nucleotide sequence is altered from wild type.

FIGURE 4

5/6




FIGURE 5




FIGURE 6

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, C07K 14/54, A61K 39/00	A3	(11) International Publication Number: WO 98/39426 (43) International Publication Date: 11 September 1998 (11.09.98)
(21) International Application Number: PCT/US98/04291 (22) International Filing Date: 5 March 1998 (05.03.98) (30) Priority Data: 08/812,121 5 March 1997 (05.03.97) US (71) Applicant (for all designated States except US): UNIVERSITY OF NEBRASKA BOARD OF REGENTS [US/US]; Regents Hall, 3835 Holdrege Street, Lincoln, NE 68598 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TRACY, Steven, M. [US/US]; 1622 N. 53rd Street, Omaha, NE 68104 (US). CHAPMAN, Nora, M. [US/US]; 1622 N. 53rd Street, Omaha, NE 68104 (US). KOLBECK, Peter [US/US]; 1416 Kingsford Drive, Carmichael, CA 95608 (US). MALONE, James [US/US]; 3420 South 50th Street, Omaha, NE 68106 (US). (74) Agents: REED, Janet, E. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103-2307 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 29 October 1998 (29.10.98)
(54) Title: COXSACKIE VIRUS VECTORS FOR DELIVERY OF NUCLEIC ACIDS ENCODING ANTIGENIC OR THERAPEUTIC PRODUCTS (57) Abstract The present invention is drawn to the use of attenuated Coxsackie virus cardiotropic virus vectors as efficient gene transfer vectors to deliver immunomodulatory or other biologically active proteins and/or antigenic epitopes in transient infections to aid in preventing, ameliorating, and/or ablating infectious viral heart disease and reducing, or ablating entirely, heart transplant rejection. Additionally, other organs or tissues may be targeted with specific picornaviruses. In particular, an attenuated CVB3 viral vector able to express a cytokine is provided. This cytokine-expressing viral vector is able to deliver the cytokine to a target tissue and reduce disease symptoms.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

In tional Application No
PCT/US 98/04291

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 C07K14/54 A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	N.M. CHAPMAN AND S. TRACY: "Can recombinant DNA technology provide useful vaccines against viruses which induce heart disease?" EUROPEAN HEART JOURNAL, vol. 16, no. suppl 0, 1995, pages 144-146, XP002072830 see the whole document --- -/--	1-6, 31, 32

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 August 1998

Date of mailing of the international search report

07/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/04291

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	N.M. CHAPMAN ET AL.,: "An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: Its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses" ARCHIVES OF VIROLOGY, vol. 135, no. 1-2, 1994, pages 115-130, XP002072831 cited in the application see the whole document -----	1-7
A	EP 0 302 801 B (PASTEUR INSTITUT) 8 February 1989 see page 2, line 10-15 see page 2, line 30-55 see page 13-16 see page 7-8 -----	1,7,8, 11,13, 15,18, 24,29, 31,32
P,X	R. ZELL ET AL.,: "Coxsackievirus B3 (CVB3) variants expressing cytokine genes as a tool to influence the local immunity in vivo" IMMUNOBIOLOGY, vol. 197, no. 2-4, 1997, pages 336-337, XP002072834 DE see the whole document -----	1-3, 12-15, 24-27, 31,32

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/04291

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 31 AND 32
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 31 AND 32
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/04291

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0302801 B	08-02-1989	FR 2619012 A	10-02-1989
		EP 0302801 A	08-02-1989
		AT 129288 T	15-11-1995
		AU 2269188 A	09-03-1989
		DE 3854591 D	23-11-1995
		DK 438288 A	10-04-1989
		WO 8901516 A	23-02-1989
		JP 1157380 A	20-06-1989
		OA 8749 A	31-03-1989
		PT 88219 A,B	30-06-1989
		US 5182211 A	26-01-1993